Raji-Human CD19 Knockout-Stable Cell Line
| Catalog Number |
CBCL-0605 |
| Price |
Online Inquiry |
| Unit Quantity |
5 x 10^6 cells / 1.0 ml |
Introduction
The Raji-Human CD19 Knockout-Stable Cell Line is generated from Raji cells through targeted knockout of human CD19 (Gene ID: 930). The expression level of human CD19 is confirmed by flow cytometry. Mutated sequences of human CD19 produced by non-homologous end joining (NHEJ) are confirmed through genomic sequencing.
Application
Useful for cell-based CD19 target-specific analysis
Background
CD19 is a B cell-specific surface glycoprotein expressed throughout B cell development (pro-B to mature B cells). It forms a co-receptor complex with CD21 and CD81, lowering the threshold for B cell activation by antigens. CD21 is a key target for CAR-T cell therapy in B cell malignancies (e.g., leukemia, lymphoma).
Product Information
| Category |
CAR-T Therapy Cell Lines |
| Cell Line Name |
Raji-Human CD19 Knockout-Stable Cell Line |
| Protein Family |
CD19 family |
| Gene |
CD19 |
| NCBI Gene ID |
930 |
| Species |
Human |
| Host Cell Line |
Raji |
| Cell Type |
Human B-cell lymphoma |
| Morphology |
Lymphoblastoid |
| Growth Properties |
Suspension |
| Selection Marker |
NA |
| Recommended Medium |
RPMI-1640 + 10% FBS |
| Freeze Medium |
Serum-free cell cryopreservation medium |
| Storage Method |
Frozen in liquid nitrogen. |
| Stability |
Validated for at least 10 passages |
| Mycoplasma |
Negative |
| Sterility Testing |
Negative |
| Shipping |
Shipping in dry ice |
| Biosafety Level |
BSL-1 |
| Caution |
For Research Use Only |
For research use only. Not for any other purpose.
